Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment.

James A. Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, New York 14853, USA.
Journal of Clinical Microbiology (Impact Factor: 4.23). 02/1997; 35(1):111-6.
Source: PubMed

ABSTRACT In specific-pathogen-free dogs experimentally infected with Borrelia burgdorferi by tick exposure, treatment with high doses of amoxicillin or doxycycline for 30 days diminished but failed to eliminate persistent infection. Although joint disease was prevented or cured in five of five amoxicillin- and five of six doxycycline-treated dogs, skin punch biopsies and multiple tissues from necropsy samples remained PCR positive and B. burgdorferi was isolated from one amoxicillin- and two doxycycline-treated dogs following antibiotic treatment. In contrast, B. burgdorferi was isolated from six of six untreated infected control dogs and joint lesions were found in four of these six dogs. Serum antibody levels to B. burgdorferi in all dogs declined after antibiotic treatment. Negative antibody levels were reached in four of six doxycycline- and four of six amoxicillin-treated dogs. However, in dogs that were kept in isolation for 6 months after antibiotic treatment was discontinued, antibody levels began to rise again, presumably in response to proliferation of the surviving pool of spirochetes. Antibody levels in untreated infected control dogs remained high.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lyme disease has become a global public health problem and a prototype of an emerging infection. Both treatment-refractory infection and symptoms that are related to Borrelia burgdorferi infection remain subject to controversy. Because of the absence of solid evidence on prevalence, causes, diagnostic criteria, tools and treatment options, the role of autoimmunity to residual or persisting antigens, and the role of a toxin or other bacterial-associated products that are responsible for the symptoms and signs, chronic Lyme disease (CLD) remains a relatively poorly understood chronic disease construct. The role and performance of family medicine in the detection, integrative treatment, and follow-up of CLD are not well studied either. The purpose of this paper is to describe insights into the complexity of CLD as a multidimensional chronic disease construct and its relevance to family medicine by means of a systematic literature review.
    01/2014; 2014:138016. DOI:10.1155/2014/138016
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Lyme disease was originally identified in Lyme, Connecticut, based upon an unusual cluster of what appeared to be patients with juvenile rheumatoid arthritis. It was subsequently identified as a new clinical entity originally called Lyme arthritis based on the observation that arthritis was a major clinical feature. However, Lyme arthritis is now called Lyme disease based upon the understanding that the clinical features include not only arthritis, but also potential cardiac, dermatologic and neurologic findings. Lyme disease typically begins with an erythematous rash called erythema migrans (EM). Approximately 4–8% of patients develop cardiac, 11% develop neurologic and 45–60% of patients manifest arthritis. The disease is transmitted following exposure to a tick bite containing a spirochete in a genetically susceptible host. There is considerable data on spirochetes, including Borrelia burgdorferi (Bb), the original bacteria identified in this disease. Lyme disease, if an organism had not been identified, would be considered as a classic autoimmune disease and indeed the effector mechanisms are similar to many human diseases manifest as loss of tolerance. The clinical diagnosis is highly likely based upon appropriate serology and clinical manifestations. However, the serologic features are often misinterpreted and may have false positives if confirmatory laboratory testing is not performed. Antibiotics are routinely and typically used to treat patients with Lyme disease, but there is no evidence that prolonged or recurrent treatment with antibiotics change the natural history of Lyme disease. Although there are animal models of Lyme disease, there is no system that faithfully recapitulates the human disease. Further research on the effector mechanisms that lead to pathology in some individuals should be further explored to develop more specific therapy.
    Journal of Autoimmunity 10/2014; 57. DOI:10.1016/j.jaut.2014.09.004 · 7.02 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A review of the literature on canine Lyme borreliosis is performed. An emphasis is put on the distribution, the epizootic particularities and the newest contributions to the subject. Numerous data are cited with a special attention on the epidemiology of the disease in Bulgaria. Lyme borreliosis is a relatively new zoonosis. For the first time, it was described by the American rheumatologist Dr. Allen Steere in 1975 in men with arthritis in the town of Lyme, Connecticut, USA hence the origin of its name. The Lyme borreliosis (LB) is caused by spirochetes from the Borrelia species, Borrelia burgdorferi sensu lato complex (0.2 х 30 µm) [1, 2]. Among the dogs in Europe and Asia, the species B. burgdorferi sensu stricto (group 1), B. garinii (group 2), B. afzelii (group 3) and B. japonica (group 4) are encountered [ 2, 3, 4, 5]. In the USA, only one species -B. burgdorferi sensu stricto is shown to be involved at this time. In most dogs, the borreliosis has a latent course. When clinically manifested, the signs are non-specific − anorexia and general depression. The most distinctive sign of the disease is the intermittent lameness, due to the developed arthritis. Very often however, the arthritis could not be detected by radiography [6]. Some papers report development of a heart block [7], neurological disorders – seizures [8] and renal failure [9]. The therapy of the disease is performed with antibiotics. Tetracyclines (doxycycline), penicillins (amoxicillin and ceftriaxone) and macrolides (azithromycin) are shown to be the most effective. In not all affected dogs however, a microbiological healing is always achieved [10, 11]. The antibiotic therapy course includes always a 3-to 4-week therapeutic protocol. The prolonged treatment of LB is related to the slow generation time of the causative agent − the organisms need 12 hours for a 2-fold increase in their numbers. Positive serological titres may be present long after the cessation of the therapy [11]. Sometimes, corticosteroids and other anti-inflammatory drugs could be administered, but always combined with antibiotics. Some studies have shown that in some cases, the therapy with the corticosteroid prednisone in subclinical infections could result in clinical manifestation of arthritis [11].

Full-text (2 Sources)

Available from
May 22, 2014